Ascletis Pharma Inc. (HKG:1672)

Market Cap	14.23B
Revenue (ttm)	2.59M
Net Income (ttm)	-283.33M
Shares Out	991.97M
EPS (ttm)	-0.29
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,258,000
Average Volume	5,760,716
Open	13.70
Previous Close	14.35
Day's Range	12.50 - 14.03
52-Week Range	1.50 - 18.75
Beta	0.56
RSI	75.34
Earnings Date	Nov 16, 2025

About Ascletis Pharma

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company’s commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of prima...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 231
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1672

Financial Performance

In 2024, Ascletis Pharma's revenue was 1.28 million, a decrease of -97.73% compared to the previous year's 56.60 million. Losses were -300.94 million, 108.0% more than in 2023.

Financial numbers in CNY